Talkmed Group

Talkmed Group EBIT Margin

Delisted·Sep 12, 2025

The EBIT Margin (Operating Margin) of Talkmed Group (5G3.SI) as of Nov 14, 2026 is 41.52 %. In the previous year, EBIT Margin (Operating Margin) was 46.59 % — a change of -10.88% (lower).

EBIT Margin

41.52 %

YoY

-10.88%

Last updated:

EBIT Margin (Operating Margin) of Talkmed Group is 2024 41.52 % . EBIT Margin (Operating Margin) of Talkmed Group was 2023 46.59 % . It decreases by -10.88% lower compared to the previous year.

For Talkmed Group, the operating (EBIT) margin of 41.5% is down versus 46.4% a few years ago.

The Talkmed Group EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2017
62.81 SGD
Jan 1, 2018
57.35 SGD
Jan 1, 2019
55.85 SGD
Jan 1, 2020
46.45 SGD
Jan 1, 2021
45.14 SGD
Jan 1, 2022
51.18 SGD
Jan 1, 2023
46.59 SGD
Jan 1, 2024
41.52 SGD
The Talkmed Group EBIT Margin history
YEAREBIT MarginYoY
41.52 %-10.88%
46.59 %-8.98%
51.18 %+13.37%
45.14 %-2.80%
46.45 %-16.83%
55.85 %-2.61%
57.35 %-8.69%
62.81 %-4.85%
66.01 %-4.64%
69.22 %-5.72%
73.42 %+11,440.35%
0.64 %-14.29%
0.74 %-7.03%
0.80 %-1.07%
0.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Talkmed Group Stock analysis

What does Talkmed Group do? Talkmed Group Ltd. is a leading healthcare company in Asia specializing in the development, manufacturing, and marketing of innovative diagnostic and therapeutic solutions in oncology. The company was founded in 2002 by Dr. Ang Peng Tiam, with a focus on providing high-quality cancer treatments. Since its inception, Talkmed Group Ltd. has become a pioneer in cancer research and treatment in Asia and has grown to become one of the largest providers of cancer treatments in the region. The company's business model is centered around offering high-quality diagnostic solutions and innovative cancer therapies to provide better patient care. They work closely with pharmaceutical companies to develop and market innovative medications and therapies that contribute to higher survival rates and improved quality of life for cancer patients. In addition, Talkmed Group Ltd. is involved in the development of medical diagnostic and monitoring devices tailored to the needs of cancer patients. They offer a range of treatments and programs that aim to provide accessible, affordable, and high-quality care for cancer patients. Overall, Talkmed Group Ltd. is an innovative company dedicated to improving the lives of cancer patients through the development, manufacturing, and marketing of diagnostic and therapeutic solutions in oncology. Talkmed Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Talkmed Group stock

EBIT Margin (Operating Margin) of Talkmed Group is 41.52 % in 2024.

EBIT Margin (Operating Margin) of Talkmed Group changed from 46.59 % to 41.52 %, representing a -10.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Talkmed Group since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Talkmed Group with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Talkmed Group

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Talkmed Group